New Perspectives in Prostate Cancer: From Pathophysiology to Novel Therapies

Dear Colleagues,

Prostate cancer (PCa) poses a significant global health challenge, with approximately nearly 1.4 million new cases and 375,000 deaths worldwide annually. The rates of occurrence range from 6.3 to 83.4 per 100,000 men. In 2020, PCa ranked as the fifth leading cause of cancer-related deaths among men.

The heterogeneity of PCa, influenced by various factors such as androgen receptor status, gene expression, and growth patterns, plays a crucial role in determining the appropriate approach to managing the disease. These factors guide the decisions between active surveillance for less aggressive forms, curative treatments like prostatectomy or radiotherapy for localized disease, or systemic therapy for advanced cancer.

Nuclear medicine techniques have gained significant importance in the assessment and treatment of PCa. These techniques offer comprehensive evaluations of tumor burden throughout the body, enabling the differentiation between patients with limited metastatic disease and those with extensive disease. In recent times, researchers have developed several nomograms that combine clinical and imaging biomarkers. These nomograms serve various purposes, such as diagnosis, prognosis, prediction, and risk stratification. However, validating their clinical utility requires a substantial amount of data. Radiomics and artificial intelligence (AI) present further opportunities in this field. They hold the potential to enhance the efficiency and accuracy of data analysis by leveraging vast amounts of information. This can lead to a deeper understanding of the molecular environment of PCa, the refinement of personalized treatment strategies, and improved predictive capabilities for patient outcomes.

In this Special Issue, we aim to highlight the latest innovations in diagnostics and personalised treatment approaches in prostate cancer, novel therapies with radioligants and DNA repair pathway targeted agents.

Dr. Christos Mikropoulos
Dr. Stergios Boussios
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• artificial intelligence
• nuclear medicine
• genomics
• personalized treatment